Natus Medical Inc (NASDAQ:BABY) has been upgraded to Hold in a report by Zacks Investment Research today.
- Updated: November 28, 2016
Only yesterday Natus Medical Inc (NASDAQ:BABY) traded -1.41% lower at $42.00. The company’s 50-day average is $40.74 and its two hundred day average is $38.82. With the last stock price up 8.18% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the date range. Volume of trade was up over the average, with 510,250 shares of BABY changing hands over the typical 358,877
Zacks Investment Research has upgraded Natus Medical Inc (NASDAQ:BABY) to Hold in a report released on 11/28/2016.
On 01/12/2016, ROTH Capital released a statement for Natus Medical Inc (NASDAQ:BABY) dropped the target price from $53.00 to $50.00. At the time, this indicated a possible upside of 0%.
Natus Medical Inc has a 52 week low of $29.54 and a one year high of $51.05 with a PE ratio of 34.15 Natus Medical Inc’s market capitalization is presently $0.
A total of 2 analysts have released a research note on the stock. 1 brokerage rating the stock a strong buy, 2 brokerages rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $42.00.
Brief Synopsis On Natus Medical Inc (NASDAQ:BABY)
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company's segment is neurology and newborn care product families. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn's environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It is organized into two strategic business units: Neurology and Newborn Care.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.